Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022GlobeNewsWire • 04/21/22
Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase DeficiencyGlobeNewsWire • 04/14/22
Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/24/22
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 02/24/22
FDA Approves Agios' Mitapivat As First Disease-Modifying Therapy For Genetic Blood DisorderBenzinga • 02/18/22
Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase DeficiencyGlobeNewsWire • 02/17/22
Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022GlobeNewsWire • 02/10/22
Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company's Strategic Vision in Genetically Defined DiseasesGlobeNewsWire • 01/10/22
Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022GlobeNewsWire • 12/22/21
Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion BurdenBenzinga • 12/14/21
Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and ExpositionGlobeNewsWire • 12/13/21
Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and ExpositionGlobeNewsWire • 12/13/21
Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and ExpositionGlobeNewsWire • 12/13/21
Why Is Agios Pharmaceuticals (AGIO) Down 24.6% Since Last Earnings Report?Zacks Investment Research • 12/03/21
Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/03/21